Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Raymond James Financial, Inc. — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.59 (market cap $4.59B), while Raymond James Financial, Inc. trades at $158.14 (market cap $30.51B). The key difference: Raymond James Financial, Inc. is far larger — about 6.6× Definium Therapeutics Inc. Common Shares's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Raymond James Financial, Inc. for 74 Days on average.
| DFTX | RJF | |
|---|---|---|
Market Cap | $4.59B | $30.51B |
Volume | 2,103,937 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $48.45 | $181.18 |
52-Week Low | $10.68 | $140.89 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $3.55B | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Raymond James Financial (RJF) trades at $157.29, down 1.4% with a bearish technical signal. The company shows strong fundamentals with consistent earnings beats, 15.4% net margin, and 18.5% ROE. Recent Q3 2026 results featured record revenues of $3.93 billion, beating estimates. Analysts maintain a Hold consensus with $184 price target, representing 17% upside potential from current levels.
RJF presents a mixed outlook with strong operational performance offset by technical weakness. The stock offers value at 13.7x P/E with dividend growth potential, but faces headwinds from rising expenses and market volatility. Institutional activity shows mixed signals with both position increases and decreases among major holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
